Document is current
Any future updates will be listed below
-
Authors
Hanamura, Toru
Yokoyama, Kozue
Kitano, Shigehisa
Kagamu, Hiroshi
Yamashita, Makiko
Terao, Mayako
Okamura, Takuho
Kumaki, Nobue
Hozumi, Katsuto
Iwamoto, Takayuki
Honda, Chikako
Kurozumi, Sasagu
Richer, Jennifer K.
Niikura, Naoki
-
Funding
Funding for this research was provided by:
Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (20K22856, 18K16266)
Tokai University School of Medicine Research Aid
Tokai University Tokuda Memorial Cancer/Genome Basic Research Grant for Young Investigators
Chugai Pharmaceutical Co. Ltd
- License Information
-
More Information
Article History
Received: 11 September 2023
Accepted: 7 January 2024
First Online: 13 February 2024
Declarations
:
: Hiroshi Kagamu has an advisory role in ImmuniT Research Inc, received honoraria from AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., and Chugai Pharmaceutical Co., Ltd. Shigehisa Kitano received honoraria from Ono Pharmaceutical Co., Bristol-Myers Squibb Co., Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., and MSD Co. Ltd, received research funding from Astellas Pharma Inc., Gilead Sciences Inc., Eisai Co., Ltd., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Takara Bio Inc., PACT Pharma Inc., Chugai Pharmaceutical Co., Ltd., and MSD Co., Ltd. Naoki Niikura received honoraria from AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Pfizer Japan Inc., Eisai Co. Ltd., and Nippon Kayaku Co. Ltd. Sasagu Kurozumi has received honoraria from Eli Lilly and Company, Daiichi Sankyo Co. Ltd, Taiho Pharmaceutical Co. Ltd, MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical, Ltd., Dinow Inc., Eisai Co., Ltd., and Novartis Japan, Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd.
: This study was conducted at the Tokai University Hospital and approved by the Ethics Committee, which conforms to the provisions of the Declaration of Helsinki (Accepted project No. 16R-279 and 20R-049).
: Participants were enrolled from May 2015 to April 2023, and written informed consent was obtained from all participants.
: Not applicable.
